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ABSTRACT
Worldwide >10 million adults and 250 000 cord blood units are available for unrelated HCT. HLA matching
and, in the case of cord blood units, cell dose are critical determinants for selecting among these donors. Once
a list of suitable adult donors or cord blood units is established, the transplantation physician must choose the
optimal donor. We review factors that go into making that decision. We conclude that for adults the optimal
donor is a male who is younger and has a larger body weight. When selecting among female adults, the optimal
donor is also younger with a larger body weight and has never been pregnant. Additional factors, which can be
considered and are relevant particularly for cord blood units, include family and medical histories, risk-
exposure history, collection site characteristics, and geographic location.
© 2007 American Society for Blood and Marrow Transplantation
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The selection of optimal donors for allogeneic
CT is a topic focused primarily on the adult volun-
eer, unrelated donor. In the related donor setting,
hen 1 suitable HLA-matched donor is available,
he choice is frequently straightforward, dictated by
onor health issues, CMV serostatus, family social
ynamics, or practical logistics. Similarly, with unre-
ated cord blood units (CBUs), cell dose and HLA
atching are the over-riding factors, although there
ay occasionally be selection considerations created
y the family and maternal history of the cord blood
onor. However, in the unrelated adult donor setting,
ven among comparably HLA-matched donors there
ay be multiple choices. A recent analysis by the
ational Marrow Donor Program (NMDP) showed
hat 56% of US patients will have 10 suitably
atched adult donors in the current NMDP ﬁle (Ta-
le 1). What factors, in addition to HLA match,
hould be used to distinguish and choose between
hese donors?
Optimal donor selection is distinguished from op-
imal graft selection. The latter concerns comparing
he merits of different graft sources and includes, eg,
he decision between a related and an unrelated donor,
n adult unrelated donor and a public CBU, or
ingle CBU and double CBU transplantation. Op-
imal graft selection is frequently dictated by insti- autional preference, physician experience, or re-
earch priorities. Optimal graft selection is beyond
he scope of this review.
Among adult unrelated donors, the role of HLA
atching has been clearly established and continues to
e reﬁned [1-8]. Similarly, with CBU the critical role
f cell dose is well accepted [9-11]. The interactions
etween CBU cell dose and HLA matching are com-
lex but have been addressed in recent publications
12,13]. The implications of HLA and cell dose for
electing adult donors and CBUs were reviewed in the
006 Education Supplement [14].
ONOR CHARACTERISTICS
An NMDP analysis of donor characteristics and
heir effect on the outcome of unrelated donor mar-
ow transplantation was reported by Kollman et al
15]. The study included 6978 unrelated donor BMTs
acilitated between December 1987 and July 1999.
onor characteristics analyzed included age, sex and
arity, race, CMV serostatus, ABO type, and HLA
atching. Although HLA matching could be evalu-
ted only at the serologic level for HLA-A and -B and
he allele-potential level for HLA-DRB1, it was found
o signiﬁcantly affect survival, DFS, aGVHD, cGVHD,
nd neutrophil engraftment.
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D. L. Confer and J. P. Miller84onor Age
In the study by Kollman et al [15], use of BM
onors who were younger had a signiﬁcant effect on
urvival and DFS of transplant recipients. In the mul-
ivariate analysis, the relative risk for survival per de-
ade of donor age was 1.10 (95% CI, 1.06-1.14, P 
001). This effect has also been reported by the Span-
sh Bone Marrow Donor Registry [16]. The effect of
ounger donor age was seen in all recipient age groups
nd was also observed when recipients with acute
eukemias and CML were analyzed independently.
ounger donor age also reduced the risk of severe
GVHD and cGVHD.
The analysis by Kollman et al examined only BM
ransplant recipients who had received myeloablative
onditioning. A more recent NMDP analysis (unpub-
ished) evaluated 7043 recipients whose transplanta-
ions occurred between January 2000 and December
004. Included in this analysis were 3022 (43%) re-
ipients of PBSC grafts and 277 (4%) CBU recipients.
he effect of younger donor age (restricted to BM and
BSC donors only) on survival at 1 yr remained sta-
istically signiﬁcant in multivariate analysis (data not
hown). Donor age was the only donor characteristic
esides HLA match that inﬂuenced recipient survival.
onor Sex and Parity
Among the adult donor population, transplanta-
ion physicians prefer male donors. Although females
omprise 58% of the total registry volunteers, males
omprise 58% of the donors actually selected for
CT. In the BM setting, some of this preference is no
oubt driven by body size and the belief that male
onors can provide a larger donation. According to
MDP data, the median BM donation by male do-
ors is 1.1 L, with 25% of males donating in excess of
.35 L. The corresponding ﬁgures for female donors
re 1.0 and 1.2 L, respectively. As a proportion of
ody weight, however, female donors make larger
onations (median, 15 mL/kg; 75th percentile, 19
ersus 12 and 14.5 mL/kg, respectively).
The analysis by Kollman et al [15] found no effect
f donor sex on survival, aGVHD, or engraftment.
owever, recipients of BM from female donors were
ore likely to develop cGVHD [15], but this effect
as restricted to female donors with prior pregnan-
able 1. Current Number of HLA Matches for 53 226 Patients Who
n
HLA-matched Donors†, n
Minimum First Quartile Median Thir
3 226 0 2 14
Patients who previously searched the NMDP registry had their se
Matching determined at intermediate resolution for HLA-A andies. Compared with males, the relative risk of iGVHD for never-pregnant females was 1.09 (95%
I, 0.96-1.24, P  .17). With a single pregnancy the
elative risk was 1.19 (95% CI, 1.0-1.43, P  .05)
nd with 2 pregnancies the relative risk was 1.40
95% CI, 1.25-1.57, P  .0001). A similar analysis of
GVHD risk versus PBSC donor parity has not been
erformed.
Males who donate PBSCs may provide a higher
ose of the CD34 cells than female PBSC donors
rrespective of body weight [17]. An analysis of
MDP donors who received a mobilizing ﬁlgrastim
ose of 10 g/kg subcutaneously for 5 days shows
hat males demonstrate a consistently higher median
reapheresis peripheral blood CD34 cell count (Fig-
re 1). The difference in median CD34 cell content
etween males and females is as large as 30%-40% for
he lighter donor weight ranges.
onor Weight
Larger donors may be preferred for BM donation
ecause of their larger total blood volume. The study
y Kollman et al [15] conﬁrmed that larger donors
rovided signiﬁcantly higher infused BM cell doses.
or donors weighing70, 70-90, and90 kg, median
ell doses were 2.95, 3.14, and 3.37  108/kg, respec-
ively (P  .0001).
As shown in Figure 1, even among PBSC donors
eceiving standard 10-g/kg daily ﬁlgrastim dosing,
earched the NMDP Registry*
Proportion with
>1 Match
Proportion with
>10 Matchesrtile Maximum
10 651 0.86 0.56
sults updated against the donor ﬁle as of April 2006.
allele level for HLA-DRB1.
igure 1. The median preapheresis peripheral blood CD34 cell
oncentration is displayed for males (solid line) and females (dashed
ine) within weight ranges of 60-120 kg. All donors received
lgrastim at a dose of 10 g/kg daily for 5 days. The median
D34 cell concentrations for male donors are higher, particularly
t the lower weight ranges. The medians for males and femalesHave S
d Qua
84
arch rencrease with increasing donor weight (P  .001).
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Optimal Donor Selection: Beyond HLA 85here appears to be a strong association between
reaphersis peripheral blood CD34 cell content and
onor weight. However, ﬁlgrastim dosing in these
onors was based on actual, unadjusted body weight,
o it is conceivable that larger donors actually received
igher doses based on lean body mass. The relation
etween donor weight and donor suitability deserves
urther examination.
ONOR TESTING RESULTS
Blood from adult donors and mothers of CBU
onors is tested during initial evaluation and the re-
ults are available to assist with optimal donor selec-
ion. Standard infectious disease testing includes HIV,
epatitis C and B viruses, human T lymphotropic
iruses I/II, syphilis and CMV. In general, CBUs are
ot stored whenever screening tests, with the excep-
ion of CMV, are positive. Some cord blood banks
outinely employ additional testing to conﬁrm that
BUs are not actively infected with CMV. Contro-
ersy exists regarding the banking of CBU where the
other tests positive for anti-HBc (antibodies to hep-
titis B core antigen). The incidence of positive test
esults is higher in certain ethnic populations and, if
hese units are excluded, CBUs with potentially good
LA matches may be precluded for those same pop-
lations.
Adult donors who test positive with screening tests
n the United States are declared ineligible; however,
uch donors may still donate in urgent circumstances.
hese donors will undergo additional conﬁrmatory
esting that clariﬁes the exact risk posed to a potential
ematopoietic cell transplant recipient.
ABO testing is also available on all adult donors
nd CBUs. ABO matching or mismatching, however,
oes not affect recipient survival, DFS, or risk of
VHD [15].
When a potential donor-recipient pair is mis-
atched at the HLA-antigen level, testing should be
erformed to conﬁrm that the recipient is not alloim-
unized against the donor’s HLA type [18,19]. The
resence of anti-HLA antibodies in the recipient,
hich recognize the donor’s HLA antigens, is associ-
ted with a high risk for nonengraftment.
The role of testing and matching for miHAs, non-
LA genetic loci, such as killer cell Ig-like receptors
KIRs), or cytokine gene polymorphisms remains to
e clariﬁed. Currently there are no data to indicate
hat matching for KIRs, minor antigens, or certain
nterleukin genes is necessary outside a research pro-
ocol.
ONOR HISTORY
Adult donors and mothers of CBU donors provide
health history and a risk-exposure history. The cealth history may reveal inherited conditions within
he family, such as RBC abnormalities or systemic
nzyme deﬁciencies that will render the donor unsuit-
ble. For adult donors the health history is more likely
o reveal conditions that will affect the safety of the
onation. If such is a donor is cleared for donation, the
ransplantation physician should still review the con-
itions for their potential to limit the likelihood of a
uccessful BM or PBSC donation. For example, a
onor with prior anesthesia difﬁculties or musculo-
keletal problems might have difﬁculty with BM do-
ation. Similarly a donor with a history of autoim-
une disease or poor venous access might be less
uitable for PBSC donation, particularly if a large
ollection is desirable.
A donor’s history (or CBU maternal donor his-
ory) of risk exposure is very important and should
outinely be reviewed by the transplantation physi-
ian. In addition to hepatitis and HIV, the risk history
eveals information about vaccinations, malaria, West
ile virus, transmissible spongiform encephalopathies
e.g., Creutzfeldt-Jakob Disease [CJD] and new vari-
nt Creutzfeldt-Jakob Disease [nvCJD]), Chagas dis-
ase, and other conditions.
OLLECTION SITE
The location of the collection site for BM, PBSCs,
r CBUs may be an issue that requires attention from
he transplantation team. Geographic location may
ffect product transportation and timing of transplan-
ation. Fresh and frozen products should be trans-
orted in validated shipping containers according to
stablished operating procedures.
Collection sites, including cord blood banks, that
re members of the NMDP network must meet initial
embership criteria and annual reevaluations. Non-
MDP sites should be evaluated for accreditation by
professional organization such as FACT, AABB, or
ACT-Netcord. Sites must also meet Food and Drug
dministration regulatory requirements where appli-
able.
When receiving products from donors outside the
nited States, additional precautions are warranted.
roducts imported must meet US regulatory and cus-
oms importation requirements. The World Marrow
onor Association (WMDA) is a voluntary associa-
ion of international registries and cord blood banks
hose members adhere to WMDA standards and pol-
cies. A WMDA accreditation program for interna-
ional donor registries has recently been established,
hich over time will provide added assurance about
nternational exchange of HCT products. Similarly,
etcord is an international association of cord blood
anks that have agreed to pursue common practices
nd accreditation for compliance with FACT-Net-
ord Standards.
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D. L. Confer and J. P. Miller86UMMARY
With respect to cord blood, once the cell-dose and
LA-matching requirements have been satisﬁed, se-
ection of the optimal CBU from a list of candidate
nits is primarily a matter of reviewing qualiﬁcations
f the represented cord blood banks and the maternal
ealth history documents of the individual units. In
ddition to these issues, for the adult unrelated donor,
here are donor-related factors that are known or
uspected to inﬂuence the overall quality of the result-
ng BM or PBSC donation. In general, it appears that
hen HLA matching is the same, the preferred donor
s younger, male, and good sized, say 80 kg. When
hoosing among female adults, in addition to age and
ody size, attention should be given to parity, with no
rior pregnancies preferable to a single pregnancy,
hich is preferable to 2 prior pregnancies.
Unfortunately, there is, as yet, no way to balance
LA matching against donor age, sex, and size. For
xample, at what age, if any, does a single-allele mis-
atch in a younger male donor become superior to 0
lleles mismatched in a 50-yr-old female with no prior
regnancies? Similarly, how does one rate the effect of
rior pregnancies against differences in age for pro-
pective female donors? The answers to these ques-
ions are unknown. Fortunately for the transplanta-
ion physician, younger female donors are more likely
o be nulliparous than older females.
An additional area of uncertainty is how to factor
onor characteristics against a proposed recipient’s
isk status. Perhaps donor factors become less impor-
ant as recipient risk increases. If HLA-matching re-
uirements are satisﬁed, no donor should be disqual-
ﬁed solely on the basis of age, sex, or size, unless a
etter donor option is readily available.
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